Fig. 1: Prevalence of anti-SARS-CoV-2 IgG antibodies across study groups and validation of the results. | Nature Communications

Fig. 1: Prevalence of anti-SARS-CoV-2 IgG antibodies across study groups and validation of the results.

From: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Fig. 1

a Left: Prevalence and 95% confidence intervals of a positive anti-SARS-CoV-2 IgG antibody test recognizing the S1 ___domain of the spike protein in the non-health care (NHC) control cohort, health care (HC) control cohort and immune-mediated inflammatory diseases (IMIDs) with and without cytokine inhibitors (CI); right: risk ratios and 95% confidence intervals of anti-SARS-CoV-2 IgG antibody positivity in the HC control cohort and IMIDs with and without cytokine inhibitors (CI) with the NHC control cohort as reference; b Comparison of anti- SARS-CoV-2 IgG positive (anti-S1+; N = 10) and negative (anti-S1; N = 10) samples (in Euroimmune ELISA) for reactivity in the chemi-luminescent anti- SARS-CoV-2 Spike S1/nucleocapsid IgG test (Yhlo Biotech) and anti-nucleocapsid IgG antibody ELISA (Immundiagnostik Inc). c Validation with in-house ELISA testing reactivities against1 the S1 ___domain of the spike protein2, the receptor binding ___domain (RBD) of the S1 ___domain of the spike protein3, extracellular ___domain (ECD) of the S2 ___domain of the spike protein and4 the nucleocapsid in anti- SARS-CoV-2 IgG negative (N = 6) and positive (N = 6) samples (in Euroimmune ELISA), COVID-19 patients with positive viral RNA test (N = 6) and patients with endemic human coronavirus (HCoV) infection (N = 5) in the pre- SARS-CoV-2 time.

Back to article page